Show Notes
Psychedelics are the next front in Big Tech's dystopia. Psymposia developed this primer for leftists in response to Donald Trump's April 18 Executive Order, which accelerates review of psychedelic drugs deemed "Breakthrough Therapies" and makes Schedule 1 drugs more accessible under Right to Try laws. This announcement made a splash in psychedelic media, where praise for the Trump administration mixes with false claims about an "end to prohibition." In this discussion, we provide important context about this Executive Order and the people who engineered this moment behind the scenes. We highlight concerns about how this initiative will be rolled out by the Trump administration, which has been accused of pay-to-play tactics at the FDA and stacking the Department of Health and Human Services with psychedelic industry evangelists. This move represents a crystallization of far-right interest in the psychedelic industry and step towards oligarch monopolization of psychedelic medicine by figures including Peter Thiel and Musk lieutenant Antonio Gracias. We end by discussing the risks of elite control over drugs that have been developed to shift identity — especially when those elites are simultaneously devoted to killing the so-called "woke mind virus" and remaking the global order in Palantir's image. Foot Notes: Executive Order (White House): https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/ President Trump Signs Executive Order to Accelerate Psychedelic Research and Access (Psychedelic Alpha): https://psychedelicalpha.com/news/president-trump-signs-executive-order-to-accelerate-psychedelic-research-and-access/ Over-the-top psychedelic promos could undermine the field's drug development efforts (STAT): https://www.statnews.com/2026/03/31/psychedelic-biotech-promotion-scrutinized-helus-atai-influencer-marketing/ Archived: https://archive.is/bv1oU Pharma lobbyists focus on a surprising new target: the FDA (STAT): https://www.statnews.com/2026/02/23/fda-lobbying-efforts-grow-under-trump-administration/ Archived: https://archive.is/wQav7 Wohin treibt die Renaissance von LSD & Co.? (WOZ) https://www.woz.ch/2609/psychedelika/wohin-treibt-die-renaissance-von-lsd-co/!NBCC4R4K3E06
More from The Psymposia Podcast
Normie, Mike, and Neşe discuss the upcoming MAHA Summit and its psychedelic pharmaceutical sponsors.
The crew discusses the FDA's September 14 psychedelic hearing, including Neşe's experience being in attendance, the financial conflicts of interest at the event, and the pseudoscientific beliefs of practitioners who gave testimony. Footnotes: Submit written comment to the FDA by October 5, 2026 https://www.federalregister.gov/documents/2026/07/14/2026-14155/considerations-for-potential-future-therapeutic-use-of-psychedelic-drugs-public-hearing-request-for
Psymposia dives into the recent Rolling Stone article — "Reggie Watts Is a Prominent Ketamine Advocate. Was It His Ex's 'Undoing'?" — and explores how the dynamics at play in that article are pervasive within the psychedelic advocacy scene. Footnotes: Reggie Watts Is a Prominent Ketamine Advocate. Was It His Ex's 'Undoing'? (Rolling Stone): https://www.rollingstone.com/tv-movies/tv-movie-features/reggie-watts-ketamine-drug-advocate-1235607828/ Ending The Silence Around Psychedelic Therapy Abuse (Mad In America): https://www.madinamerica.com/2021/09/ending-silence-psychedelic-therapy-abuse/ Cover Story: Power Trip (Psymposia): https://www.psymposia.com/powertrip-2/ The Psychedelic Syndicate (Psymposia): https://www.psymposia.com/psychedelic-syndicate-executive-summary-silicon-valley-maps-lykos-mdma-fda-billionaires/index.html
Psymposia interviews YouTube documentarian @Alex-Novell about his experience with Andrew Callaghan and Channel 5, drug legalization, and creating documentary films. Thumbnail terminator image provided by Alex Novell.
Psymposia discusses takeaways from their "Psychedelic Conversion Therapy" series and reflects on the ten year anniversary of their "Coming Out of the Psychedelic Closet" series.